# CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

> **NCT03566043** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **REGENXBIO Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Mucopolysaccharidosis Type II (MPS II)

## Interventions

- **GENETIC:** RGX-121

## Key facts

- **NCT ID:** NCT03566043
- **Lead sponsor:** REGENXBIO Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-27
- **Primary completion:** 2023-11-27
- **Final completion:** 2025-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566043, "CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03566043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*